HULUWA(SH:605199) Zheng Quan Zhi Xing·2025-07-29 16:21Summary of Key Points Core Viewpoint - The company, Hainan Huluwa Pharmaceutical Group Co., Ltd., has announced a guarantee of RMB 30 million for its wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd., to support its operational financing needs [1][2]. Group 1: Guarantee Details - The guarantee amount provided is RMB 30 million, with a total guarantee balance of RMB 222.16 million for Guangxi Weiwei [1]. - The guarantee is part of a broader financing plan where the company has approved a total loan financing limit of up to RMB 1.5 billion for the year 2025 [2]. - The guarantee does not include any counter-guarantee [2][3]. Group 2: Financial Overview of Guangxi Weiwei - Guangxi Weiwei has total assets of RMB 924.51 million and total liabilities of RMB 712.83 million as of the first quarter of 2025 [4]. - The net profit for Guangxi Weiwei for the first quarter of 2025 was a loss of RMB 10.05 million, compared to a profit of RMB 2.79 million for the entire year of 2024 [4]. Group 3: Board Approval and Risk Management - The board of directors approved the guarantee during a meeting on April 17, 2025, as part of the company's authorized operational activities [4]. - The company maintains that the guarantee is necessary for the stable development of Guangxi Weiwei and that the overall risk is manageable due to the company's ability to monitor its subsidiary's creditworthiness [4][5]. Group 4: Cumulative Guarantee Situation - As of the announcement date, the company and its subsidiaries have no overdue guarantees, with a cumulative guarantee balance of RMB 317.04 million, which accounts for 45.26% of the company's latest audited net assets [5].